Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Berzosertib||VX-970|VE-822|M6620||ATR Inhibitor 10||Berzosertib (VX-970) is a small molecule inhibitor of ATR, which may enhance the sensitivity of chemotherapeutic agents resulting in antitumor activity (PMID: 25269479, PMID: 32109490).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|ARID1A Q456*||colorectal cancer||sensitive||Berzosertib||Preclinical - Cell line xenograft||Actionable||In a preclinical study, Berzosertib (VX-970) treatment in colorectal cancer cells homozygous for ARID1A Q456* resulted in decreased cell survival in culture, and tumor growth inhibition in cell line xenograft models (PMID: 27958275).||27958275|
|Unknown unknown||Advanced Solid Tumor||not applicable||Berzosertib||Phase I||Actionable||In a Phase I trial, Berzosertib (VX-970) treatment resulted in complete response in 9% (1/11) and stable disease in 36% (4/11) of patients with advanced solid tumors (J Clin Oncol 34, 2016 (suppl; abstr 2504)).||detail...|
|ARID1A mutant||ovarian clear cell carcinoma||sensitive||Berzosertib||Preclinical - Cell line xenograft||Actionable||In a preclinical study, Berzosertib (VX-970) treatment in ovarian clear cell carcinoma cells harboring an ARID1A mutation resulted in decreased cell survival and induction of DNA damage and apoptosis in culture, and tumor growth inhibition in cell line xenograft models (PMID: 27958275).||27958275|
|ATM loss||colorectal cancer||sensitive||Berzosertib||Phase I||Actionable||In a Phase I trial, Berzosertib (VX-970) treatment resulted in complete response for more than 19 months in a colorectal cancer patient harboring ATM loss (J Clin Oncol 34, 2016 (suppl; abstr 2504)).||detail...|
|IDH1 R132H||Advanced Solid Tumor||sensitive||Berzosertib||Preclinical - Cell culture||Actionable||In a preclinical study, transformed cells expressing IDH1 R132H demonstrated increased sensitivity to Berzosertib (VX-970)-induced growth inhibition in culture (PMID: 28148839).||28148839|
|ATM del||prostate cancer||sensitive||Berzosertib||Preclinical - Cell culture||Actionable||In a preclinical study, ATM-deficient prostate cancer cell lines were sensitive to treatment with Berzosertib (VX-970) in culture, demonstrating inhibition of cell growth (PMID: 32127357).||32127357|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT04052555||Phase I||Berzosertib||Testing the Addition of an Anti-cancer Drug, M6620, to the Usual Treatment (Radiation Therapy) for Chemotherapy-Resistant Triple-Negative and Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast Cancer||Recruiting|
|NCT02595892||Phase II||Berzosertib Gemcitabine||Gemcitabine Hydrochloride Alone or With VX-970 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer||Active, not recruiting|
|NCT02487095||Phase Ib/II||Berzosertib Topotecan||Trial of Topotecan With VX-970, an ATR Kinase Inhibitor, in Small Cell Lung Cancer||Recruiting|
|NCT02589522||Phase I||Berzosertib||VX-970 and Whole Brain Radiation Therapy in Treating Patients With Brain Metastases From Non-Small Cell Lung Cancer||Recruiting|
|NCT02627443||Phase II||Carboplatin + Gemcitabine Berzosertib||Carboplatin and Gemcitabine Hydrochloride With or Without ATR Kinase Inhibitor VX-970 in Treating Patients With Recurrent and Metastatic Ovarian, Primary Peritoneal, or Fallopian Tube Cancer||Recruiting|
|NCT03718091||Phase II||Berzosertib||M6620 (VX-970) in Selected Solid Tumors||Recruiting|